1. European Parliament and the Council of the European Union: Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code relating to medicinal products for human use. 2004, Official Journal L-311, [
http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf
],
2. European Parliament and the Council of the European Union: Amended by Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. 2004, Official Journal L 136, [
http://www.gmp-compliance.org/guidemgr/files/DIR_2004_27_EN.PDF
] (accessed August 14, 2013),
3. European Commission: Guideline on the readability of the labelling and package leaflet of medicinal products for human use. Revision 1. 2009, [
http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-2/c/2009_01_12_readabilty_guideline_final.pdf
] (accessed September 18, 2013),
4. Quality Review of Documents Group: QRD Annotated Template: Revision of the Product Information. 2010, London: European Medicines Agency, [
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000134.jsp&mid=WC0b01ac0580022c59&jsenabled=true
] (accessed September 18, 2013),
5. Quality Review of Documents: Draft Version of the QRD Annotated Template for External Consultation. 2009, [
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000134.jsp
],